BioStock: Curasight cancels rights issue and evaluates alternative financing
In mid February, Curasight announced a DKK 51.2 million rights issue to accelerate clinical development of uTREAT and uTRACE. Now, about a month later, the company has decided to cancel the rights issue and is evaluating alternative sources of financing. Following the announcment, the share price traded down.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se